Safety & Adverse Effects
Study register · detail Phase-1-RCT (Pharmakokinetik + Sicherheit, gesunde Probanden) · Safety & Adverse Effects · 2020

A phase 1, randomized, pharmacokinetic trial of the effect of different meal compositions, whole milk, and alcohol on cannabidiol exposure and safety in healthy subjects.

Clear benefit GRADE Moderate 74 citations
Samplen = 29 Pat.
Durationup to 96 hours after dosing
ControlFasted state
EndpointAUC0-∞ and Cmax
Blindingoffen
DesignPhase-1-RCT (Pharmakokinetik + Sicherheit, gesunde Probanden)
Cannabinoidcbd
Max. dose750.0 mg
Routeoral
Key finding

High-fat meals increase CBD bioavailability the most (3,8-fold AUC, 5,2-fold Cmax), followed by low-fat meals, whole milk, and alcohol.

Summary

Phase 1 RCT (n=29 fasted reference group) on CBD 750 mg (Epidiolex) and the effect of food on exposure: AUC 3,8-fold higher with high-fat meal (vs. fasted), Cmax increased 5,2-fold; low-fat meal +2,7-fold AUC; whole milk +2,4-fold AUC; alcohol +1,6-fold AUC. No serious adverse events.

P
PopulationHealthy adults, n=29 (fasted), n=15 (high-fat/calorie meal), n=14 (low-fat/calorie meal), n=15 (whole milk), n=14 (alcohol)
I
InterventionSingle oral dose of 750 mg pharmaceutically pure CBD (Epidiolex/Epidyolex, 100 mg/mL solution) under various food conditions
C
ControlFasted state
O
OutcomeAUC0-∞ increased 3,8-fold (high-fat), 2,7-fold (low-fat), 2,4-fold (whole milk), 1,6-fold (alcohol) vs. fasted; Cmax increased 5,2-fold, 3,8-fold, 3,1-fold and 1,9-fold respectively; no clinically relevant effects on tmax or t½
Confidence in the evidence
Moderate

The third of four GRADE levels, the effect estimate is probably reliable.

Downgraded for
Imprecision
Quality profile
Sample size
Blinding Open-label
Effect size Clear benefit
Citations / year
Authors
Crockett J, Critchley D, Tayo B, Berwaerts J, Morrison G.
DOI 10.1111/epi.16419
Design: Phase-1-RCT (Pharmakokinetik + Sicherheit, gesunde Probanden)
Share
Abstract
<h4>Objective</h4>The pharmacokinetics (PK) and safety of single oral 750-mg doses of a plant-derived pharmaceutical formulation of highly purified cannabidiol (CBD; Epidiolex in the USA and Epidyolex in Europe; 100-mg/mL oral solution) were assessed in healthy adults following a high-fat/calorie meal (n = 15), a low-fat/calorie meal (n = 14), whole milk (n = 15), or alcohol (n = 14), relative to the fasted state (n = 29).<h4>Methods</h4>Blood samples were collected until 96 hours postdose in each period and evaluated by liquid chromatography and tandem mass spectrometry. PK parameters (maximum observed plasma concentration [C<sub>max</sub> ], area under the plasma concentration-time curve from time zero to the last observed quantifiable concentration, area under the concentration-time curve from time zero to infinity [AUC<sub>0-∞</sub> ], and time to maximum plasma concentration [t<sub>max</sub> ]) of CBD and its major metabolites were derived using noncompartmental analysis.<h4>Results</h4>CBD exposure increased by 3.8-fold for AUC<sub>0-∞</sub> and 5.2-fold for C<sub>max</sub> when CBD was administered with a high-fat/calorie meal versus fasted. To a lesser extent, a low-fat/calorie meal enhanced CBD exposure versus fasted with a 2.7-fold increase in AUC<sub>0-∞</sub> and a 3.8-fold increase in C<sub>max</sub> . Similarly, when dosed with whole milk, CBD exposure increased versus fasted by 2.4-fold for AUC<sub>0-∞</sub> and 3.1-fold for C<sub>max</sub> . Modest elevations in CBD exposure occurred when it was dosed with alcohol: 1.6-fold for AUC<sub>0-∞</sub> and 1.9-fold for C<sub>max</sub> . No clinically relevant effect of any test condition on CBD t<sub>max</sub> or t<sub>½</sub> versus the fasted state was apparent. The same trend was seen for the CBD metabolites, except that 7-carboxy-cannabidiol t<sub>max</sub> was considerably longer when CBD was administered with alcohol (14 vs 4 hours fasted). Inter- and intrasubject variability in PK parameters was moderate to high during the trial.<h4>Significance</h4>CBD and metabolite exposures were most affected by a high-fat/calorie meal. CBD exposures also increased with a low-fat/calorie meal, whole milk, or alcohol, but to a lesser extent. CBD was tolerated, and there were no severe or serious adverse events during the trial.

The impediment to action advances action. — Marcus Aurelius